These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 27743144)

  • 21. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma.
    Majd N; de Groot J
    Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484
    [No Abstract]   [Full Text] [Related]  

  • 22. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
    Londhe VY; Date V
    Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Checkpoint inhibitor immunotherapy for glioblastoma: current progress, challenges and future outlook.
    Gedeon PC; Champion CD; Rhodin KE; Woroniecka K; Kemeny HR; Bramall AN; Bernstock JD; Choi BD; Sampson JH
    Expert Rev Clin Pharmacol; 2020 Oct; 13(10):1147-1158. PubMed ID: 32862726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Microglia-Centered Combinatorial Strategies Against Glioblastoma.
    Martins TA; Schmassmann P; Shekarian T; Boulay JL; Ritz MF; Zanganeh S; Vom Berg J; Hutter G
    Front Immunol; 2020; 11():571951. PubMed ID: 33117364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glioblastoma-associated microglia and macrophages: targets for therapies to improve prognosis.
    Poon CC; Sarkar S; Yong VW; Kelly JJP
    Brain; 2017 Jun; 140(6):1548-1560. PubMed ID: 28334886
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
    Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
    World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives.
    Cuoco JA; Benko MJ; Busch CM; Rogers CM; Prickett JT; Marvin EA
    World Neurosurg; 2018 Dec; 120():302-315. PubMed ID: 30196171
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current vaccine trials in glioblastoma: a review.
    Xu LW; Chow KK; Lim M; Li G
    J Immunol Res; 2014; 2014():796856. PubMed ID: 24804271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combining immunotherapy with radiation for the treatment of glioblastoma.
    Chow KK; Hara W; Lim M; Li G
    J Neurooncol; 2015 Jul; 123(3):459-64. PubMed ID: 25877468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination immunotherapy strategies for glioblastoma.
    Chan HY; Choi J; Jackson C; Lim M
    J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
    Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
    Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them.
    Sengupta S; Mao G; Gokaslan ZS; Sampath P
    Cancer Gene Ther; 2017 Mar; 24(3):121-129. PubMed ID: 27767090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Advances in Immunotherapy for Glioblastoma.
    Mende AL; Schulte JD; Okada H; Clarke JL
    Curr Oncol Rep; 2021 Jan; 23(2):21. PubMed ID: 33496872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunotherapy targeting glioma stem cells--insights and perspectives.
    Li Z; Lee JW; Mukherjee D; Ji J; Jeswani SP; Black KL; Yu JS
    Expert Opin Biol Ther; 2012 Feb; 12(2):165-78. PubMed ID: 22200324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments.
    Feldman L
    Front Immunol; 2024; 15():1384249. PubMed ID: 38994360
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DCVax®-L--developed by Northwest Biotherapeutics.
    Polyzoidis S; Ashkan K
    Hum Vaccin Immunother; 2014; 10(11):3139-45. PubMed ID: 25483653
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.